Albireo Pharma (NASDAQ: ALBO)
Albireo Pharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Albireo Pharma Company Info
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
News & Analysis
Why Albireo Pharma Stock Is Skyrocketing Today
The company reported positive data from a clinical trial.
Is This a MannKind Killer?
We'll know soon enough if Biodel's BIOD-123 has what it takes.
The Big Money Says to Sell MannKind
Should you be dumping this stock, too?
FDA Gives Treats to a Few Drugmakers
Looks like the agency still knows how to use that approval stamp.
Will These Drugs Get Past the FDA?
We'll know soon enough.
Low-Profile Stocks for High Returns
These underrated stocks could be tomorrow's big winners.
Valuation
Earnings Transcripts
Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript
ALBO earnings call for the period ending September 30, 2021.
Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript
ALBO earnings call for the period ending June 30, 2021.
Albireo Pharma, Inc. (ALBO) Q1 2021 Earnings Call Transcript
ALBO earnings call for the period ending March 31, 2021.
Albireo Pharma, Inc. (ALBO) Q4 2020 Earnings Call Transcript
ALBO earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.